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Abstract
Despite significant progress in hepatitis C (HCV) treatment, global viral eradication remains a challenge. An in-depth map of
its genome diversity within the context of structural and immunological constraints could contribute to the design of pan-
genotypic antivirals and preventive vaccines. For such analyses, extensive information is only available for the highly prev-
alent HCV genotypes (GT) 1a and 1b. Using 647 GT1a and 408 GT1b full-genome sequences obtained from the Los Alamos
database, we found that respectively 3 per cent and 82 per cent of all codon positions are under positive and negative selec-
tive pressure, suggesting variation mainly accumulates due to random genetic drift. An association between conservation
and both structured RNA and secondary protein structures confirmed the important role of structural elements at nucleo-
tide and at amino acid level. Remarkably, CD8þT-cell epitopes in HCV GT1a were significantly more conserved, while at the
same time containing more sites under positive selection. Similarly, CD4þT-cell epitopes were significantly more conserved
in both HCV subtypes, but under less positive selective pressure in GT1b and more negative selective pressure in GT1a.
In contrast, B-cell epitopes in both subtypes were less conserved and under less stringent negative selection. These findings
argue against immune selective pressure as the main force of between-host diversifying evolution. Despite its high
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variability, HCV is under strict evolutionary constraints, most probably to keep its genes and proteins functional during the
replication cycle. These are encouraging findings for vaccine and drug design, which could consider these newly established
genetic diversity profiles.
Key words: HCV GT1a and GT1b; conservation; selective pressure; RNA structure; T- and B-cell epitopes; protein secondary
structure
1. Background
Hepatitis C virus (HCV) infections are associated with life-
threatening diseases such as liver cirrhosis and hepatocellular
carcinoma, remaining a global threat to public health (Webster
et al. 2015). This enveloped RNA virus is classified into seven
HCV genotypes (GTs) and more than 50 subtypes (Smith et al.
2014). HCV’s single-stranded RNA genome encodes a large poly-
protein with a single open-reading frame that translates into
four structural and six non-structural (NS) proteins (Weiser and
Tellinghuisen 2102).
To date, global eradication of HCV infections is challenged
by the lack of a preventive vaccine that induces broad reactive
immunity (Liang 2013). Two main approaches have been pro-
posed in vaccine development, with the first targeting the hu-
moral immune response as neutralizing antibodies (NAbs) play
a major role in the clearance of HCV infections (Drummer 2014).
However, a recombinant E1/E2 candidate tested in humans re-
sulted into relatively low titres of NAbs, modest levels of neu-
tralization and limited cross-neutralizing potential (Ray et al.
2010). Studies in humans and chimpanzees showed that T-cell
responses are multifunctional and sustained over time, evolv-
ing towards the generation of T-cell-based vaccines (Liang
2013). The first T-cell-based vaccine with NS3-NS5B genes incor-
porated resulted into high levels of both CD8þand CD4þHCV-
specific T cells targeting multiple HCV antigens, in humans
(Swadling et al. 2014), yet no reactive immunity was established
towards all circulating genotypes and subtypes.
Treatment progress is much more encouraging. Current
anti-HCV treatment strategies rely on the administration of
direct-acting antivirals (DAAs) that target HCV NS3/4A protease,
NS5A or NS5B polymerase, and offer virological response rates
of 95 per cent and higher for all circulating HCV genotypes (Yau
and Yoshida 2014). Nevertheless, there is still a need to develop
potent pan-genotypic drugs, characterized by minimal drug–
drug interactions, affordable price tags and activity against HCV
variants associated with drug resistance to current DAAs
(Franco et al. 2014). Even with such high treatment successes,
global eradication is not to be expected soon. To achieve viral
eradication, the number of undiagnosed HCV patients urgently
needs to be reduced (Mathis 2012; Wei and Lok 2014), which
could enhance treatment coverage and prevent further trans-
mission. High-risk and high-prevalence patient groups need to
be screened with priority, given their high reported re-infection
rates (Micallef et al. 2007; Martin et al. 2013; De Vos and
Kretzschmar 2014).
The needed progress in vaccine design and therapeutic cure
is hampered by the high evolutionary rate of HCV, which allows
rapid adaptation to changing environments (Forns et al. 1999;
Bailey et al. 2012; Li et al. 2015). Different molecular mecha-
nisms have been proposed to shape viral evolution in general,
including natural selection by the host immune system, selec-
tive pressures exerted by antiviral treatment, replication capac-
ity, recombination, epidemiological factors such as migration,
genetic bottlenecks and genetic drift, for which the two latter
are largely influenced by population size (Preciado et al. 2014).
Focusing on HCV, molecular evolution involves multiple com-
plex processes characterized by temporal variations that con-
stantly rearrange the architecture of the intra-host viral
population. More specifically, viral variants can escape from
strong selective pressure exerted by the host innate and adap-
tive immune system (Neumann-Haefelin and Thimme 2011;
Heim and Thimme 2014). Under drug selective pressure, the
heterogeneous intra-patient viral population can trigger the de-
velopment of drug-resistant strains, with the resulting changes
not equally distributed across the genome (Martell et al. 1992; Le
Guillou-Guillemette et al. 2007; Gray et al. 2011). The replication
capacity in a specific environment of a virus carrying a specific
amino acid variant will influence whether the variant gets lost
or becomes fixed in the viral population (Vandamme 2009;
Neumann-Haefelin and Thimme 2011; Rehermann 2013), lead-
ing to genetic conservation in certain viral regions and adaptive
evolution in others (Forns et al. 1999; Holmes 2003 ).
A previous in-depth analysis of genetic diversity and selec-
tive pressure in HCV genotypes 1–6 has shown that 39 per cent
of all positions in the HCV full-genome had a consensus residue
with a frequency of at least 95 per cent common for all geno-
types (Cuypers et al. 2015). Positive selective pressure was iden-
tified for only 0.23 per cent of the HCV full-genome positions
(Cuypers et al. 2015). The current study aims to advance these
findings by integrating information on nucleotide and amino
acid conservation, positive and negative selective pressure, and
structural and immunological constraints. More specifically, a
comprehensive map of structured RNA, protein secondary
structures and immune epitopes will help to better understand
viral evolution and how diversity is shaped by the host immune
system and the tolerance to mutations (Gray et al. 2011; Snoeck
et al. 2011; Bittar et al. 2013). These analyses require large data-
sets, hence our focus on the two most prevalent subtypes of the
widely distributed HCV genotype 1.
2. Methods
2.1 Full-length genome sequence dataset
Full-length sequences (9,000 nt or more) of HCV GT1a and GT1b
were downloaded from the Los Alamos HCV Sequence Database
(LANL, http://hcv.lanl.gov) (Kuiken et al. 2008). Duplicates and
sequences from non-human hosts were deleted, with a single
sequence randomly selected per patient. Since all sequences of
this study were submitted to Los Alamos before 2008, patients
were considered to be DAA-naive, despite limited availability of
treatment information.
Sequences were aligned using reference sequence H77, with
an in-house developed pairwise alignment tool-chain (Cuypers
et al. 2015; Libin 2014). Alignments were manually edited in
Seaview V4.0 (Gouy et al. 2010) to improve their quality. HCV
subtype assignment was checked based on clustering with
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reference sequences from Los Alamos using a maximum-
likelihood (ML) tree constructed by RAxML V8.0.20 (Stamatakis
2014). Four sequences showed a discordant result compared to
their genotype assignments in LANL, confirmed by the COMET
(Struck et al. 2014) and Oxford HCV subtyping tools (Alcantara
et al. 2009), resulting into removal or inclusion of the sequence
according to the genotype assigned by the ML tree and subtyp-
ing tools. Sequences containing in-frame stop codons or lacking
sequence information for any of the HCV proteins were re-
moved, resulting into a dataset of 647 HCV GT1a and 408 HCV
GT1b full-genome sequences.
2.2 Representativeness of the dataset
The representativeness of the GT1a and GT1b full-genome data-
sets was evaluated with respect to virus diversity of the world-
wide HCV GT1a and 1b epidemic. For each protein, probability
distributions of pairwise nucleotide diversity calculated using
HCV GT1a and GT1b full-genome datasets were compared with
those of an evaluation dataset downloaded from the LANL data-
base (Mann–Whitney U test, P<0.05). This evaluation dataset
contained all HCV GT1a and GT1b sequences present in Los
Alamos, irrespective of any specific protein or genomic region,
with only one sequence randomly selected per patient.
Additionally, the full-genome datasets and evaluation datasets
were compared by phylogenetic analysis using a ML approach.
2.3 Conserved residues and sites under positive or
negative selective pressure
Within each subtype, the most prevalent amino acid or nucleo-
tide at each position was defined as the consensus residue,
even when its frequency was less than 50 per cent (Roebuck
2011). A position was defined as weakly conserved, conserved
or highly conserved, when the frequency (x) of a consensus resi-
due was<95 per cent, 95 per cent x< 99 per cent, or99 per
cent, respectively (Supplementary Table S1). Detection of selec-
tive pressure was performed using the fixed-effect likelihood
(FEL) method, implemented in HyPhy v2.2.1 (Pond et al. 2005),
which accommodates site-by-site variation. An amino acid po-
sition was considered to be under positive selective pressure if
the ratio of non-synonymous and synonymous amino acid sub-
stitutions at that codon (dN/dS ratio) was >1 and the P< 0.05 as
significance level for the likelihood ratio test (Supplementary
Table S2). Contrary, amino acid positions with dN/dS<1, and a
P< 0.05, were defined as positions under negative selective
pressure.
2.4 Structural and immunological constraints
Linear HCV epitopes of T and B cells from assays that were able
to identify epitopes were collected according to the Immune
Epitope Database (IEDB) (http://www.iedb.org/) and mapped to
their corresponding positions based on the reference sequence
H77. T-cell epitopes restricted to the major histocompatibility
complex (MHC) class I and II were analysed separately since
CD4þT cells may not drive viral escape mutations (Fuller et al.
2010). HCV genotype 1 epitopes were only included when they
were reported in humans. Moreover, only CD8þand CD4þT-cell
epitopes described by at least two independent research groups
were considered. Nevertheless, all B-cell epitopes were included
because very few epitopes were reported by more than one re-
search lab. Subtype information was not provided for many sub-
jects in these studies, resulting in potential misclassification.
Epitope annotations without subtype specification were allo-
cated to both HCV subtype datasets.
A consensus RNA structure was predicted for each HCV sub-
type by the free energy minimization approach implemented in
RNAalifold (Bernhart et al. 2008), based on ten random datasets
of the GT1a and GT1b sequence alignments (mean, SD) because
the maximum input of this software was set at 300 sequences.
For each nucleotide position, RNAalifold assigns either a ‘stem’
or a ‘loop’, with nucleotide pairings within stems clearly indi-
cated. Regions with more than five consecutive residues pre-
dicted as a stem were considered as a structured RNA region,
without considering other secondary RNA structures (Jossinet
et al. 2007; Kuznetsov et al. 2008).
Secondary structures for each of the ten HCV proteins were
predicted based on either the sequence-based prediction soft-
ware PSIPRED (Jones 1999; Buchan et al. 2013) or the structure-
based prediction software 2Struc (Klose et al. 2010), at least
when crystallized or nuclear magnetic resonance (NMR)
structures were not present in the Protein Data Bank (PDB)
(www.rcsb.org; Herman et al. 2000). Supplementary Table S3
summarizes the coverage of proteins by PDB data and their
sequence similarity in comparison to reference sequence H77
(NC_004102). Protein secondary structures of regions not cov-
ered by PDB data were predicted with 2Struc or PSIPRED.
2.5 Generalized linear regression analysis
Given the datasets of the HCV GT1a and GT1b full-genomes
and individual viral proteins, general linear regression analy-
sis was performed to identify associations (1) between nucleo-
tide conservation and structured RNA, (2) between amino acid
conservation and the presence of epitopes or protein second-
ary structures, (3) between positive selected positions and im-
munological or structural constraints, (4) between negative
selective pressure and immunological and structural con-
straints, and (5) between amino acid conservation and selec-
tive pressure. Odds ratios were estimated with a 95 per cent
confidence interval, with an odds ratio considered as signifi-
cant if its P was<0.05 after multiple testing corrections using
the Benjamin–Hochberg method (Benjamini and Hochberg
1995). For multivariate analysis, sequence conservation or
positive/negative selective pressure was considered as depen-
dent variables and the different constraints as independent
variables.
2.6 Resistance
Natural variation at positions associated with resistance devel-
opment to drugs of the three DAA drug classes was studied
more in depth in the context of structural and immunological
constraints. Based on in vitro and/or in vivo data, drug resistance
amino acid positions have been identified for all NS3/4A prote-
ase inhibitors (n¼ 15), NS5A inhibitors (n¼ 9), and NS5B poly-
merase inhibitors (n¼ 14) (Cuypers et al. 2015). The term
resistance-associated variant (RAV) is used rather than the re-
cently introduced term resistance-associated substitution, to
indicate that natural variation at population level is studied,
and no assumptions are made on the actual substitution.
However, all variants are identified with respect to the generally
accepted reference strains (H77 for GT1a and Con1 for GT1b). As
such, Q80K means, for example, the 80K variant for which the
reference strain has the amino acid Q and does not imply a sub-
stitution from Q to K.
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Figure 1. Representativeness of datasets.(A) The comparison of pairwise nucleotide (nt) diversity for the variable protein E2 of HCV GT1a (left) and HCV subtype GT1b
(right). A strong overlap is shown between the full-genome dataset used (red), and the validation dataset consisting of all available sequences coding for gene E2 (blue).
Similar overlaps in density plots were obtained for the different genome regions (not shown here). (B) HCV GT1a E2 sequences from the study (green), and validation
(blue) datasets were aligned together and analysed in a bootstrapped (n ¼ 1,000) ML tree using RaxML. Strains with an identical identification are displayed in black.
The genetic distance is indicated underneath the tree. Similar results were obtained for other viral regions, as well as for HCV GT1b.
4 | Virus Evolution, 2016, Vol. 2, No. 2








3.1 Representativeness of the dataset
Large overlaps in diversity distributions were observed between
the full-genome datasets and an evaluation dataset combining
all available sequences for all proteins (Fig. 1A). Additionally,
similarities were identified in the dispersion between strains
from the full-genome dataset and the strains of the evaluation
dataset (Fig. 1B). This suggests that both HCV GT1a and GT1b
full-genome datasets can be considered as representative for
the HCV GT1a and 1b sequence diversity in the complete Los
Alamos database.
3.2 Conserved residues and positively selected positions
Only 15.7 per cent of the amino acid positions in the full-
genome were defined as weakly conserved (Supplementary
Table S1). Conversely, 60.8 per cent and 23.5 per cent were
defined as, respectively, conserved and highly conserved within
HCV GT1a, in comparison to 15.9 per cent and 68.5 per cent
within HCV GT1b. At the nucleotide level, a higher proportion of
weakly conserved positions was observed (26.4% for HCV GT1a
and 29.0% for GT1b).
The FEL method predicted positive selective pressure at, re-
spectively, 3.3 per cent and 2.9 per cent of the full-genome posi-
tions in HCV GT1a and GT1b (Supplementary Table S2).
According to the codon-specific approach in FEL, 82.8 per cent
of all positions across the HCV GT1a and GT1b full-genome
were detected to be under negative selective pressure.
3.3 Mapping structural and immunological constraints
Figures 2 and 3, respectively, illustrate for each HCV GT1a and
GT1b position the extent of nucleotide and amino acid diversity,
detection of positive selective pressure, and different structural
and immunological constraints.
Figure 2. Mapping of sequence diversity, positive selective pressure, and structural and immunological constraints on the HCV GT1a full-genome. Layers: (1) average
nucleotide diversity (per bar: 20%); (2) amino acid diversity (per bar: 20%); (3) positively selected sites; (4) RNA structures with five consecutive nucleotides predicted as
“stem”; (5) protein secondary structures: a-helices (purple) and b-strands (orange); (6) CD4þ T-cell epitope positions; (7) CD8þ T-cell epitope positions; (8) B-cell epitope
positions; (9) HCV proteins (reference strain: H77, NC_004102). Inner circle: 3D structures of proteins for which PDB resolution covers more than 50% of the protein
(PyMOL V1.5 (http://www.pymol.org/), Circos V0.62 (http://circos.ca/; Krzywinski et al. 2009).
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Figure 3. Mapping of sequence diversity, positive selective pressure, structural and immunological constraints, on the HCV GT1b full-genome. Same layers as in
Figure 2.
Figure 4. Alignment of structural constraints on the HCV GT1a vs HCV GT1b genome. The HCV genome is represented as a linear concatenation of all ten viral proteins
(reference strain: H77), showing data for structured RNA regions (blue) and for protein secondary structures as a-helices (purple) or b-strands (orange).
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Structured RNA regions, containing more than five consecu-
tive residues predicted as a stem, were evenly distributed across
the entire genome, covering 48 per cent and 46 per cent of the
HCV GT1a and GT1b genome, respectively (Fig. 4). Of all viral
proteins, protein E2 contained the lowest proportion of nucleo-
tide positions in structured RNA regions (39.52% 6 0.39%), and
protein NS4A the highest proportion (72.72% 6 3.33%), for both
HCV subtypes.
The lowest proportion of protein secondary structures (a-
helix and b-strand structures) was observed for the core protein
(21.6% 6 2.55%), E2 (28.7% 6 3.89%), and NS5A (32.1% 6 0.64%)
proteins (Fig. 4). On the contrary, more than 81 per cent of the
amino acid positions of proteins NS5B and p7 were located
within a-helix or b-strand structures. The distribution was very
similar for both subtypes.
Overall, for CD8þT-cell epitopes, no significant difference in
the number of mapped positions was observed between both
HCV subtypes, in contrast to a higher number of CD4þT-cell epi-
topes in HCV GT1a and a higher number of B-cell epitopes for
HCV GT1b. Within each subtype, B-cell epitopes and CD4þT-cell
epitopes covered more positions than CD8þT-cell epitopes (49%
and 73% vs. 17% for HCV GT1a, 67% and 50% vs. 17% for HCV
GT1b). For both B-cell epitopes and CD4þT-cell epitopes, the
highest proportion of positions was mapped in the core protein
(Fig. 5). For CD4þT-cell epitopes, in addition to the core protein,
high coverage of positions in proteins E1, NS3, NS4A, and NS4B
was also observed. HCV proteins with the lowest coverage of
epitopes were NS2 and NS5A for CD8þT-cell epitopes, E2, p7
and NS2 for CD4þT-cell epitopes, and p7 and NS3 for B-cell
epitopes.
3.4 Combining different layers of data: univariate and
multivariate analyses
For both HCV GT1a and GT1b, associations of sequence conser-
vation or selective pressure with structural or immunological
constraints were studied at the genome and individual protein
level (Supplementary Tables S4A–C).
3.4.1 Univariate analysis: conservation
Supplementary Table S4A shows the associations between con-
servation and structural or immunological constraints. At the
full-genome level, structured RNA regions displayed a signifi-
cant positive correlation with nucleotide conservation in both
subtypes (OR(GT1a): 1.13; OR(GT1b): 1.14). Moreover, this
correlation was also significant for the individual core protein
in the HCV GT1b dataset and for NS5B in the GT1a dataset.
Across the HCV full-genome, B-cell epitopes and amino acid
conservation were negatively correlated (OR(GT1a): 0.49;
OR(GT1b): 0.59). This negative correlation was also significant
for individual proteins: E2, NS5A, and NS5B for HCV GT1a and
NS5A for GT1b strains. For both subtypes, a positive correlation
between amino acid conservation and CD4þT-cell epitopes was
observed (OR(GT1a): 1.82; OR(GT1b): 1.74) when using the entire
genome, and this was confirmed for protein E2 in GT1b. In the
full-genome of HCV GT1a, the presence of b-strands was posi-
tively correlated with amino acid conservation (OR: 1.37).
As expected, amino acid conservation displayed a significant
negative correlation with positive selective pressure (OR(GT1a):
0.39; OR(GT1b): 0.38), as well as a positive correlation with nega-
tive selective pressure (OR(GT1a): 8.12; OR(GT1b): 4.79). Both cor-
relations remained significant for the majority of the viral
proteins separately (Supplementary Table S4A).
3.4.2 Univariate analysis: positive or negative selective pressure
Supplementary Table S4B shows associations between positive
selection and different constraints. There was a significant low
proportion of positions under positive selective pressure in
structured RNA regions for the HCV GT1a full-genome
(OR(GT1a): 0.65) and in a-helices for GT1b (OR(GT1b): 0.27).
Of note, analyses on individual proteins yielded no significant
results.
Supplementary Table S4C shows correlations between nega-
tive selective pressure and different constraints, which are
more pronounced compared to correlations with positive selec-
tive pressure. In both HCV subtypes, b-strands had a significant
enrichment of amino acid positions under negative selective
pressure (OR(GT1a): 1.83; OR(GT1b): 1.53), while the reverse was
true for B cell (OR(GT1a): 0.53; OR(GT1b): 0.45) and CD8þT-cell
epitopes (OR(GT1a): 0.73; OR(GT1b): 0.72). Additionally, for the
HCV GT1a dataset, a-helices had a low number of positions
characterized by dN/dS<1, while CD4þT-cell epitopes and
structured RNA regions had more sites under negative selective
pressure.
3.4.3 Multiple factors shaping HCV genotype 1 genomic
diversity
As shown in Figure 6A and Supplementary Table S5, multivari-
ate analysis suggested that in both subtypes, the only indepen-
dent predictor for lower amino acid conservation was coverage
Figure 5. Alignment of immunological constraints on the HCV GT1a vs HCV GT1b genome. The HCV genome is represented as linear concatenation of the ten proteins
(reference strain: H77), representing data on B-cell epitopes (dark green), CD8þ T-cell epitopes (red) and CD4þ T-cell epitopes (orange), for HCV GT1a and 1b separately.
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by B-cell epitopes. There were, however, multiple independent
predictors for higher conservation: coverage by CD8þT-cell epi-
topes, at least for HCV GT1a; CD4þT-cell epitopes; protein sec-
ondary structures (both a-helices and b-strands); and structured
RNA regions. Predictors for a low number of sites under positive
selective pressure were within a-helix and b-strand structures
in the HCV GT1a full-genome (Fig. 6B). An independent predic-
tor for a high number of sites under positive selective pressure
was identified for HCV GT1a, CD8þT-cell epitopes, in contrast to
CD4þT-cell epitopes for which the inverse relation was true for
the GT1b dataset. A higher proportion of sites under negative
selective pressure was identified in regions covered by a-helices
and b-strands in both subtypes (Fig. 6C), while a lower propor-
tion of sites was detected for B-cell epitopes and CD8þT-cell
epitopes, also for both subtypes. Additionally, for the HCV GT1a
full-genome, the presence of CD4þT-cell epitopes was an inde-
pendent predictor for higher coverage by positions under nega-
tive selective pressure.
3.5 Resistance
For each of the drug resistance amino acid positions, structured
RNA, CD8þand CD4þT-cell epitopes and B-cell epitopes, and
protein secondary structures were mapped (Table 1). The major-
ity of the fifteen drug resistance-related positions in protein
NS3 was covered by structured RNA (10/15) or located within
b-strand structures (12/15), expect one position embedded in an
a-helix. More positions were targeted by B-cell compared to
CD8þT-cell epitopes (Table 1A). Also for drug resistance-related
positions in NS5A, a high number was covered by B-cell epi-
topes and mapped to structured RNA (Table 1B) and NS5B (Table
1C). In fact, this was a general phenomenon across all drug-
targeted regions.
Additionally, the frequency distribution of amino acids at
each amino acid position involved in drug resistance is indi-
cated in Tables 1A–C. For NS3/4A protease inhibitors, a high
natural prevalence was demonstrated for drug resistance-
related variant Q80K in HCV GT1a-infected patients (39.3%).
For NS5A inhibitors, several resistance-related variants had a
relatively high natural prevalence, such as M28V for HCV GT1a
(4.2%) and Y93H for HCV GT1b (3.9%). Moreover, NS5B variants
C316N and S556G were present in 31.5 per cent and 8.4 per cent
of the DAA-naive HCV GT1b-infected individuals.
4. Discussion
HCV’s high evolutionary rate allows rapid adaptation to chang-
ing environments and subsequent escape from strong immune
and treatment pressures, hampering both the development of
vaccines and antiviral drugs. To investigate multiple driving
factors of HCV genetic variability, this study provides a compre-
hensive map of HCV GT1a and GT1b full-genome genetic diver-
sity integrating information on conservation, immune selective
pressure, and immunological and structural constraints. The
HCV subtypes 1a and 1b are the most prevalent worldwide with
extensive availability of public data, giving our analysis suffi-
cient statistical power. The full-genome datasets were found to
be representative for the viral diversity observed worldwide in
HCV GT1a and GT1b epidemics. Our findings contribute to the
understanding of HCV evolution (Gray et al. 2011; Snoeck et al.
2011) and the interplay between HCV genetic diversity and host
immunity (Bittar et al. 2013; Dolan et al. 2013).
A high proportion of genome positions in both subtypes was
identified as conserved or highly conserved. Among all full-
genome positions, only 3 per cent was found to be under posi-
tive selective pressure, predominantly found in the envelope
glycoproteins. For both HCV GT1a and GT1b genomes, more
than 82 per cent of all positions were observed to be under neg-
ative selective pressure, suggesting that variation mainly accu-
mulates due to random genetic drift. At population level, HCV
seems to follow the neutral model of evolution.
Figure 6. Multivariate analysis of residue conservation or selective pressure, with structural and immunological constraints. Multiple linear regression analysis was
performed for nucleotide (structured RNA) or amino acid (all other comparisons) conservation (A, left), positive selective pressure (B, middle) and negative selective
pressure (C, right). Odds ratios with 95 per cent confidence intervals (CI) are indicated for HCV GT1a (red) and HCV GT1b (blue).
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Table 1. Positions involved in drug resistance for NS3/4A protease inhibitors, NS5A inhibitors and NS5B polymerase inhibitors.
(A) NS3/4A protease inhibitor resistance-related positions
RAVs (H77) V36MLA F43SV T54SA V55A Y56H Q80KR V107I S122GR I132V R155K A156STV V158I D168AVEYT IV170AV M175L
Natural prevalence
HCV GT1a
V97.4 F98.8 T97.1 V96.1 Y98.8 Q57.4 V98.9 S94.1 I98.3 R98.3 A100 V98.9 D98.6 I96.1 L98.8
L1.2 L1.1 S1.7 I2.0 H1.1 K39.3 T1.1 G4.6 S1.1 A1.1 C1.1 F1.1 V2.8 E1.1
S1.1 S0.1 V1.1 Y1.1 F0.1 D1.1 R1.1 V0.5 K0.6 E0.2 P1.1 X0.1






V99.0 F100 T97.8 V100 Y82.3 Q95.6 V100 S79.6 V73.7 R99.3 A100 V100 D99.0 V65.6 M99.0
L0.5 S2.2 F17.4 L3.7 G12.3 I25.6 P0.5 E1.0 I34.4 L1.0









(B) NS5A inhibitors resistance-related positions
RAVs (H77) M28TV P29SX Q30EHR L31MV P32LX H58D E62D A92K Y93HNC
Natural prevalence
HCV GT1a
M94.0 P98.9 Q97.5 L97.7 P98.9 H94.3 E96.9 A98.4 Y97.8
V4.2 Q1.1 L1.2 M1.1 G1.1 P2.9 D1.7 Y1.1 T1.1
P1.1 H0.9 P1.1 C1.7 I1.1 P0.5 C0.6






L97.1 P99.8 R91.4 L96.3 P100 P93.4 Q96.1 A97.3 Y95.8
M2.5 X0.2 Q7.1 M3.4 S3.4 E2.0 T1.2 H3.9
V0.2 K1.0 I0.3 T1.7 K0.7 V0.7 F0.3
F0.2 L0.3 L0.7 R0.5 G0.5









(C) NS5B polymerase inhibitors resistance-related positions
RAVs (H77) L159F S282T C316Y V321A V368T N411S M414TI A421V Y448H P495LS A553T G554S S556G D559GN
Natural prevalence
HCV GT1a
L98.9 S98.8 C98.8 V99.9 S98.6 N98. 6 M98.5 A84.5 Y98.6 P98.4 A89.6 G89.8 S89 D89.8
I1.1 G1.1 G1.1 I0.1 N1.1 I1.1 F1.1 V12.7 G1.1 1.6 9.8 9.8 9.8 9.6






L94.8 S99.8 C67.8 V99.5 S99.8 N100 M99.8 A94.1 Y99.5 P100 A99.5 G99.5 S88.9 D98.3
F5.2 T0.2 N31.5 I0.5 P0.2 I0.2 V5.7 C0.3 0.3 0.3 G8.4 1.5
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4.1 Sequence conservation is higher in structured
regions
Structured RNA regions were associated with nucleotide conser-
vation in both HCV GT1a and GT1b (Heim and Thimme 2014),
revealing that genomic structures play important roles during
the viral life cycle, as has been described for the RNA internal
ribosome entry site in the 50-untranslated region (Filbin and
Kieft 2011; Berry et al. 2011). The same association was also sig-
nificant in the HCV GT1a dataset for the NS5B gene, consistent
with a cis-acting replication element in NS5B whose conserved
RNA structure is essential for bringing the 50 and 30 ends of the
genome (You et al. 2004; Tuplin et al. 2012). Structured RNA
regions were also negatively correlated with evidence of posi-
tive selective pressure, while positions under negative selective
pressure were enriched for HCV GT1a, however not confirmed
in the multivariate analysis. The need to maintain RNA struc-
ture restricts the possibilities for protein evolution, and amino
acid changes as a result of positive selective pressure might dis-
rupt RNA secondary structure (Tuplin et al. 2012). This shows
that for RNA viruses, selective pressure may not be properly
measured by only investigating amino acid changes. There is a
need for methods to measure selective pressure at nucleotide
level.
Multivariate analysis showed an enrichment of conserved
amino acid residues in regions containing a-helix and b-strand
structures. A negative association with positive selective pres-
sure further illustrates the importance of both a-helices and b-
strands, which was only found in HCV GT1a, while previously
also reported for HIV (Canducci et al. 2009). Then again, negative
selective pressure was significantly associated with both a-
helices and b-strands in both subtypes. These findings are in
agreement with both protein secondary structures being impor-
tant for protein functions, in contrast to what was reported by
Snoeck et al. for HIV (Snoeck et al. 2011). Maintaining secondary
structure exerts a negative selective pressure on the genome to
minimize amino acid changes that may impair protein func-
tions (Shabalina et al. 2013). However, it is worth to mention
that 3D structure information for HCV proteins is not so ex-
tended as for HIV proteins. Additionally, it needs to be noted
that both for RNA and protein secondary structures, correla-
tions with positively selected sites were only significant for HCV
GT1a, potentially due to the larger amount of data available for
this subtype.
4.2 B-cell and T-cell epitopes
The IEDB database contains more B-cell epitopes for HCV GT1b
compared to GT1a, with only few epitopes reported by two or
more research groups. The inclusion of all available B-cell epi-
topes could have overestimated the number of B-cell epitope
positions in the HCV genome. Moreover, the majority of B-cell
assays focuses on structural proteins, resulting into high cover-
age rates for the core protein and the E2 hypervariable region.
For T-cell epitope investigations, a stricter selection was possi-
ble, MHC class I (CD8þT-cell epitopes)- and MHC class II
(CD4þT-cell epitopes)-restricted epitopes were only taken into
account when reported by two or more research groups. Most
HCV-infected individuals display only few HCV-specific CD8þT-
cell responses (Rehermann 2013), and thus, as expected, a lower
number of positions is covered by CD8þT-cell epitopes than by
B-cell epitopes in our analysis.
Both MHC class epitopes were analyzed separately since
CD4þT cells are believed not to drive viral escape (Fuller et al.
2010), while CD8þT cells have been shown to contribute to vi-
ral escape (Bowen and Walker 2005). Until recently, a general
HCV GT1a peptide set was used to analyze T-cell epitopes
in individuals infected with any genotype, resulting into a
higher quality of described epitopes in GT1a compared to
GT1b. Unfortunately, not all studies in the database had HCV
genotype information available, resulting in the allocation of
HCV GT1 epitopes without subtype specification to both HCV
subtype datasets, potentially introducing biases in the
analysis.
For HCV proteins NS2 and NS5A, low coverage was observed
for both T-cell epitopes, compared to B-cell epitopes. This dif-
ference might be explained by the fact that the NS2 protein is a
‘short-lived’ protein (Chevaliez and Pawlotsky 2006), and the
discovery that protein NS5A impairs both the innate and adap-
tive immune response to promote chronic HCV infections
(Kriegs et al. 2009). Moreover, the lowest numbers of B-cell epi-
tope positions were observed for proteins p7 and NS3, while
for NS3 a high coverage by CD4þT-cell epitopes was found. For
p7, it is probably due to the unusual architecture of the ion
channel, which harbours hydrophobic pockets (OuYang et al.
2013). For NS3, it might be due to the role of this protein in viral
escape from adaptive immune responses (Horner and Gale
2013).
4.3 The host immune systemmay be not the driving
force of HCV variability
Amino acid substitutions assist in viral escape from immuno-
logical responses, expecting B- and CD8þT-cell epitope posi-
tions to be under positive selective pressure (Holmes 2003). In
the multivariate analysis, positively selected sites were en-
riched in CD8þT-cell epitopes of GT1a only. No significant
Table 1. Continued
(C) NS5B polymerase inhibitors resistance-related positions







Respectively, 15, 9, and 14 positions were identified as being associated with drug resistance to (A) NS3/4A protease inhibitors, (B) NS5A inhibitors, and (C) NS5B poly-
merase inhibitors. For each of these positions, the constraints structured RNA, protein secondary structures and T- and B-cell epitopes were mapped. Positions covered
by constraints in both datasets were colored in grey. When only mapped for HCV GT1a, the position was indicated in red and only for HCV GT1b sequences in blue. For
each of the three drug classes, the natural prevalence of RAVs is listed, using H77 as reference. Frequencies are indicated in superscript, and the amino acid variants
are ranked according to decreasing frequency. Amino acid substitutions known to confer drug resistance towards DAAs are indicated in bold, for both HCV subtypes.
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correlation was found for B-cell epitopes, while for CD4þT-cell
epitopes, a negative correlation was observed, although only in
GT1b. B- and CD8þT-cell epitopes were independent predictors
of a lower proportion of positions under negative selective pres-
sure, while for CD4þT-cell epitopes the correlation was the re-
verse, at least in GT1a. Together these results confirm the
hypothesis that CD4þT cells are not driving viral escape (Fuller
et al. 2010) and suggest that humoral immune selective pres-
sure is unlikely to act as driving force of variation. Differently,
CD8þT-cell immune response may have some impact on the
HCV genome.
T-cell responses are much more likely to be identified in
conserved viral regions since T-cell assays have been developed
using conserved peptides, and this may explain in part why
conserved residues were found to be enriched within CD4þand
CD8þT-cell epitope positions. Nevertheless, the observation
that conserved sites do contain epitopes is useful in the vaccine
field as T-cell-based vaccines incorporating conserved seg-
ments are underway. For CD4þT-cell epitopes, a similar associ-
ation has been observed for HIV (Sanjuan et al. 2013). The
significant correlation of CD8þT-cell epitopes with both positive
selective pressure and amino acid conservation argues that
while immune cellular selective pressure does exist, it may not
be the main force for diversifying evolution. For B-cell epitopes,
a negative correlation was found with amino acid conservation.
Overall, these findings suggest that the host immune system
may not be the driving factor of HCV genetic diversity, at least
from a population perspective, given that we only analyzed
between-host genetic diversity. A larger proportion of diversity
due to immune selective pressure can be expected in the con-
text of host immune genetic background (Kuniholm et al. 2010).
This may be related to the fact that B cells that contain HCV re-
ceptors have been identified as natural reservoirs of HCV
(Inokuchi et al. 2009; Ito et al. 2011), and HCV also infects T cells
(Blackard et al. 2004; Kondo et al. 2007) although the exact
mechanism is yet unknown.
4.4 Drug resistance-associated positions are found in
highly structured regions
Drug RAVs in all three target genes, located near the active site
of the proteins (Elfiky et l. 2013; Meeprasert et al. 2014; Nettles
et al. 2014), were consistently found in regions with a high cov-
erage of structured RNA regions and folding of protein b-
strands. Additionally, a higher number of RAVs was mapped to
B-cell compared to CD8þT-cell epitopes, which could be ex-
plained by higher abundance, yet active sites or enzymatic
pockets of viral proteins would be expected to be less accessible
for NAbs. All three drug targets harboured particular RAVs with
a high natural prevalence, consistent with what has been re-
ported before (Dietz et l. 2015; Lawitz et al. 2015; Costantino
et al. 2015): NS3 variant Q80K (GT1a: 39.3%), NS5A variants
M28V (GT1a: 4.2%), and Y93H (GT1b: 3.9%) and NS5B variants
C316N (GT1b: 31.5%) and S556G (GT1b: 8.4%).
4.5 Limitations
The study only focused on HCV GT1a and GT1b given limita-
tions in the number of viral sequences available for other HCV
genotypes in the Los Alamos database and in the structural in-
formation present in the IEDB and PDB databases. For those
HCV GT1a sequences for which sampling location was known, a
large proportion was from the USA, potentially explaining the
high prevalence of the NS3 natural variant Q80K in this study
(McCloskey et al. 2015). Concerning data for B-cell epitopes, a
bias was introduced since only linear epitopes were considered,
and relaxed inclusion criteria were used compared to T-cell epi-
topes. Restricted information was available for 3D protein struc-
tures (Supplementary Table S3), necessitating structural
predictions for regions lacking PDB data. Nucleotide positions
assigned as stems were considered to be structured RNA re-
gions, excluding other regions such as loops, junctions, helices,
and bulges from the analysis.
5. Conclusions
This in-depth study of HCV GT1a and GT1b by mapping con-
straints onto the full-genome shows a strong sequence conser-
vation of structured regions, even across sites mapped by
immune epitopes, emphasizing the important role of genomic
and protein structures in the viral life cycle. The selective pres-
sure analysis indicates that the immune selective pressure pre-
sent does not act as a main force for HCV between-host
diversifying evolution, suggesting HCV diversity has been accu-
mulating mainly due to random genetic drift. Despite its high
genetic variability, HCV GT1 is under strict evolutionary con-
straints, most probably to preserve the inherent functions of
HCV proteins such as their interactions with host proteins dur-
ing the viral life cycle. Since the design of a broad reactive vac-
cine is challenged, the implementation of genotype-specific and
even geographically tailored vaccine immunogens should be
explored.
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